(Reuters) - Europe's drug regulator on Thursday recommended addition of a rare type of spinal inflammation as a side-effect of Johnson & Johnson's COVID-19 vaccine.
It was also assessing reports of capillary leak syndrome following inoculation with Moderna's shot.
Already a subscriber? Log in
Get 20% OFF The Star Digital Access
Cancel anytime. Ad-free. Unlimited access with perks.
